Fierce Pharma

MARCH 19, 2024

This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nat | 2024 marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the Danish drugmaker’s red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation.

Medicine 316

Medicine 316

MedCity News

MARCH 19, 2024

AstraZeneca’s Fusion Pharmaceuticals acquisition is the latest in a wave of M&A activity that includes recent deals by Eli Lilly and Bristol Myers Squibb. The lead Fusion program is in mid-stage clinical development for treating advanced prostate cancer.

Pharmaceutical 121

Pharmaceutical Leads Biopharma Pharma 121

Fierce Pharma

MARCH 19, 2024

After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.

221

221

MedCity News

MARCH 19, 2024

In order to effectively address the nursing shortage, hospitals must embrace three key products on the market that has been proven to alleviate nurse burnout, according to Syl Trepanier, chief nursing officer at Providence.

Marketing 106

Marketing 106

Advertisement

Distribution

Fierce Pharma

MARCH 19, 2024

Guiding AbbVie through an extraordinary decade-plus, riding the success of juggernaut inflammatory disease drug Humira and softening the landing upon its decline, Richard Gonzalez continues to reap | In his final full year as AbbVie’s CEO, Richard Gonzalez pulled down a compensation package worth $25.7 million, according to the company’s proxy filing.

220

220

Pharmaceutical Commerce

MARCH 19, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, John Hoffman, Principal, Advocate for Success, LLC talks about his 'Health Equity Spotlight' panel and advocacy accomplishments.

Pharma 105

Pharma 105

MedCity News

MARCH 19, 2024

At the MedCity INVEST conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, health benefits in the context of value-based care will be one of several topics of discussion at the boutique healthcare investment event. Register today!

Healthcare 99

Healthcare Healthcare 99

Fierce Pharma

MARCH 19, 2024

After a two-year stint under Merck & Co. veteran Frank Clyburn, New York’s International Flavors & Fragrances (IFF) is stripping away a major component of its healthcare persona. | New York's IFF—which dabbles in food, beverage, beauty and pharmaceutical supply chains, among others—has agreed to sell its pharma solutions business to French plant-based ingredient maker Roquette for up to $2.85 billion.

Pharma 206

Pharma Food Healthcare Healthcare 206

European Pharmaceutical Review

MARCH 19, 2024

Under a new deal, Novartis has agreed to acquire US-based biopharma company IFM Therapeutics, for a total of up to $835 million. As part of this new agreement, Novartis has exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM. Therefore, under the acquisition, Novartis has full rights to IFM Due’s portfolio of small molecule Stimulator of Interferon Genes (STING) antagonists, IFM confirmed.

Biopharma 98

Biopharma Medicine Patients Pharmaceutical 98

Fierce Pharma

MARCH 19, 2024

Twelve years after Takeda's Iclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. | Twelve years after Takeda's Iclusig earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. regulator has signed off on a wider use.

FDA 188

FDA Patients 188

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Technology

MARCH 19, 2024

In addition to drug discovery deals, NVIDIA also announced partnerships with J&J MedTech and GE Healthcare for genAI in MedTech.

Healthcare 112

Healthcare Healthcare 112

Fierce Pharma

MARCH 19, 2024

Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. | Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy therapy.

FDA 187

FDA 187

MedCity News

MARCH 19, 2024

Do you advise self-insured employers? The 2023 Benefit Consultant Sentiment INDEX offered robust insights and cast a spotlight on the evolving roles of employers as they navigate the changing healthcare landscape. Your insights offer leading, innovative points of view that can guide employers and peers. Join us for this year’s survey!

Insurance 85

Insurance Consulting Healthcare Healthcare 85

Fierce Pharma

MARCH 19, 2024

Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. | Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument.

141

141

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Technology

MARCH 19, 2024

The new initiative aims to spur innovation and mobilisation of sectors to drive women’s health research.

111

111

Fierce Pharma

MARCH 19, 2024

Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. | Madrigal's Rezdiffra became the first drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH) just a few days ago. Now, the company looks to support the upcoming launch by selling shares.

Sales 130

Sales FDA Pharmaceutical 130

Pharmaceutical Technology

MARCH 19, 2024

The US FDA has granted approval to Orchard Therapeutics' Lenmeldy for specific forms of metachromatic leukodystrophy (MLD).

FDA 98

FDA 98

PharmaVoice

MARCH 19, 2024

Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

Side effects 98

Side effects Marketing 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

pharmaphorum

MARCH 19, 2024

AstraZeneca upgrades its radiopharma alliance with Fusion Pharma, opting to buy the biotech outright in a deal worth around $2 billion

Pharma 86

Pharma 86

European Pharmaceutical Review

MARCH 19, 2024

According to research by InsightAce Analytic Pvt. Ltd., the global continuous bioprocessing market is expected to value $1,067.8 million by 2031. While the market was valued at $255.9 million in 2023, the report predicted it will witness a CAGR of 19.72 percent between 2024-2031. The research explained that companies are looking to reduce manufacturing costs and increase productivity, which is driving implementation of this type of bioprocessing.

Marketing 70

Marketing Manufacturing Pharmaceutical 70

pharmaphorum

MARCH 19, 2024

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah

Marketing 78

Marketing 78

Eversana Intouch

MARCH 19, 2024

Every year, America celebrates and acknowledges the vital role of women in American history with a designated Women’s History Month in March. In recognizing the specific achievements women have made across the years, we also recognize those achievements didn’t come without challenges. And this month, we’re bringing to light the challenges in women’s healthcare that we can help solve and make history together.

Healthcare 59

Healthcare Healthcare Marketing Prescription 59

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

pharmaphorum

MARCH 19, 2024

Johnson & Johnson has allied with NVIDIA to bring artificial intelligence into operating rooms and accelerate the adoption of digital tech in surgery

73

73

Pharmaceutical Technology

MARCH 19, 2024

Rising numbers of counterfeit drugs are entering pharmaceutical supply chains, necessitating advanced track-and-trace systems.

Pharmaceutical 64

Pharmaceutical 64

pharmaphorum

MARCH 19, 2024

Johnson & Johnson has allied with NVIDIA to bring artificial intelligence into operating rooms and accelerate the adoption of digital tech in surgery

62

62

Clarify Health

MARCH 19, 2024

With soaring healthcare spending and poor health outcomes posing significant challenges, the healthcare industry is crying out for higher-value care. At the forefront of this revolution is the rising use of various types of healthcare provider data and deep analytics to assess provider performance and build cost-effective, quality networks. Health plans can utilize these resources to navigate the turbulent waters of healthcare cost and quality, ultimately enhancing overall outcomes.

Networking 52

Networking Healthcare Healthcare Healthcare Provider 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Commerce

MARCH 19, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, Michael Galarraga, LPC, ATR-BC, Pennsylvania State Representative, OutCare Health offers his thoughts on the breakout session and his experience in mental health counseling.

Patients 52

Patients Pharma 52

PM360

MARCH 19, 2024

Every year in March, the city known for keeping it weird turns it up a notch with the multi-audience conferences and festival known to locals as “South By.” But before the film and music festivals turn the energy “up to 11” in Austin, the interactive conference offers a platform for companies to showcase new technologies and discuss the impact of applied innovation.

Healthcare 52

Healthcare Healthcare Pharmacology Medicine 52

PharmExec

MARCH 19, 2024

The commitment to advancing the fields of oncology and nuclear medicine is not just about adopting new technologies, but also about embracing a more profound change in how care is delivered.

Medicine 52

Medicine 52

Nixon Gwilt Law

MARCH 19, 2024

Watch leading AI attorneys Rebecca Gwilt, Reema Taneja, and Sam Pinson as they cover: How the federal government and the states are regulating AI tools and functions in digital health today Key areas of risk for digital health companies to audit and examine to de-risk their AI tools and services Fundamental principles for AI deployment to prepare digital health companies for compliance with impending regulatory changes in 2024/2025 You’ll walk away from this video with a better understanding of

Government 52

Government Leads 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management